ReviewChinese journal of natural medicines2016
Bitter melon: a panacea for inflammation and cancer.
Review in Chinese journal of natural medicines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04661267 (A Randomized, Double-Blind, Placebo-Controlled Trial of Regenexx Stem Cell Support Formula), which is not on this map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled Trial of Regenexx Stem Cell Support Formula
Who cites it
63 citing papers in PubMed.
- Natural Products as Modulators of the DNA Damage Response and Oncogenic Signaling in Breast Cancer Therapy.International journal of molecular sciences · 2026Review
- Box-Behnken Design Optimization of High-Pressure Processed Bitter Melon (International journal of molecular sciences · 2026Article
- MAP30, a type Ⅰ ribosome-inactivating protein, inhibits hepatocellular carcinoma by inducing apoptosis through mitochondria.Medicine · 2026Article
- Antiviral Potential ofBiomedicines · 2026Review
- Natural compounds targeting glycolysis and TME in ovarian cancer: from metabolic crosstalk to therapeutic potential.Frontiers in pharmacology · 2026Review
- Targeting notch signaling pathway in esophageal cancer: from molecular insights to therapies.Oncology reviews · 2026Review
- Molecular insights into charantin and β-carotene biosynthesis in bitter gourd (Momordica charantia L.): Gene expression dynamics and metabolite profiling.Journal, genetic engineering & biotechnology · 2025Article
- Targeting Triple-Negative Breast Cancer with Momordicine-I for Therapeutic Gain in Preclinical Models.Cancers · 2025Article
- Momordica charantia phytoconstituents can inhibit human T-lymphotropic virus type-1 (HTLV-1) infectivity in vitro and in vivo.Journal of neurovirology · 2025Article
- Multidimensional Uses of Bitter Melon (Current organic synthesis · 2025Review
- Targeting ferroptosis: a promising avenue for ovarian cancer treatment.Frontiers in immunology · 2025Review
- Genome-Wide Analysis of the Serine Carboxypeptidase-like (SCPL) Protein Family of Bitter Gourd and Functional Validation ofInternational journal of molecular sciences · 2024Article
- Metabolomics Revealed the Effects ofFoods (Basel, Switzerland) · 2024Article
- Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes.Molecular cancer therapeutics · 2024Article
- An Integrative Medicine Educational Program for Radiation Oncology Patients: Patient-Reported Outcomes.Advances in radiation oncology · 2024Article
- Herbal Medicine-Derived Exosome-Like Nanovesicles: A Rising Star in Cancer Therapy.International journal of nanomedicine · 2024Review
- Promising roles ofJournal of agriculture and food research · 2023Article
- Transcriptomic Analysis of the Response of Susceptible and Resistant Bitter Melon (International journal of molecular sciences · 2023Article
- Article
- Therapeutic Candidates for Alzheimer's Disease: Saponins.International journal of molecular sciences · 2023Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Nature is a rich source of medicinal plants and their products that are useful for treatment of various diseases and disorders. Momordica charantia, commonly known as bitter melon or bitter gourd, is one of such plants known for its biological activities used in traditional system of medicines. This plant is cultivated in all over the world, including tropical areas of Asia, Amazon, east Africa, and the Caribbean and used as a vegetable as well as folk medicine. All parts of the plant, including the fruit, are commonly consumed and cooked with different vegetables, stir-fried, stuffed or used in small quantities in soups or beans to give a slightly bitter flavor and taste. The plant is reported to possess anti-oxidant, anti-inflammatory, anti-cancer, anti-diabetic, anti-bacterial, anti-obesity, and immunomodulatory activities. The plant extract inhibits cancer cell growth by inducing apoptosis, cell cycle arrest, autophagy and inhibiting cancer stem cells. The plant is rich in bioactive chemical constituents like cucurbitane type triterpenoids, triterpene glycosides, phenolic acids, flavonoids, essential oils, saponins, fatty acids, and proteins. Some of the isolated compounds (Kuguacin J, Karaviloside XI, Kuguaglycoside C, Momordicoside Q-U, Charantin, α-eleostearic acid) and proteins (α-Momorcharin, RNase MC2, MAP30) possess potent biological activity. In the present review, we are summarizing the anti-oxidant, anti-inflammatory, and anti-cancer activities of Momordica charantia along with a short account of important chemical constituents, providing a basis for establishing detail biological activities of the plant and developing novel drug molecules based on the active chemical constituents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.